PMPRB takes jurisdiction over medicine (again) following Federal Court of Appeal remand
Pharma in Brief
JULY 7, 2020
The PMPRB accepted that there was a slightly elevated incidence of adverse reactions as well as higher efficacy for DIFFERIN XP when compared to DIFFERIN. In this context, the PMPRB noted that “no topical acne product…is considered unsubstitutable”, based on expert evidence.
Let's personalize your content